Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
ABOUT
PRICE TARGET
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-03-27 | Reverse | 1:5 |
| 2025-11-28 | Reverse | 1:8 |
| 2025-07-21 | Reverse | 1:3 |
| 2025-03-18 | Reverse | 1:12 |
| 2023-07-28 | Reverse | 1:20 |
| 2020-11-09 | Reverse | 5:8 |
| 2020-05-26 | Reverse | 1:20 |
| 2008-11-13 | Forward | 5:1 |
ETFS HOLDING THIS STOCK
PRICE
$0.74 ▲ UP 0.35% (+$0.00)About INVO Fertility, Inc.
https://www.invofertility.com ↗INVO Fertility, Inc., founded in 2007 in Sarasota, FL, is a revenue-generating fertility company also developing clinical-stage assets in oncology and autoimmune diseases.
INDUSTRY
A PRODUCT INVO FERTILITY, INC. IS KNOWN FOR
INVOcell is a proprietary device enabling intravaginal culture for fertilization and early embryo development, offering a more accessible and intimate assisted reproductive technology option through INVO Fertility.
INVO Fertility in 2025
INVO Fertility Reports Massive Q1 Net Loss Following Strategic Decision to Divest NAYA Therapeutics and Refocus on Core Fertility Business
INVO Fertility announced a significant strategic shift in April 2025 to divest its majority stake in NAYA Therapeutics to concentrate on its core fertility operations. This was followed by its Q1 2025 financial results in May, which reported a staggering net loss of $(17.4) million, primarily due to a non-cash impairment charge of $14.6 million related to the NAYA acquisition. This event highlighted a major restructuring and strategic pivot for the company, moving away from a dual focus on fertility and oncology.
INVO Fertility Restructures Executive Team to Accelerate Clinic Acquisition Strategy
INVO Fertility realigned its executive leadership to sharpen its focus on an aggressive growth strategy centered on acquiring and establishing new fertility clinics. The former CFO, Andrea Goren, was appointed as Chief Business Officer and CEO of the clinic-focused subsidiary, INVO Centers LLC, to spearhead M&A activity, while the company's controller, Terah Krigsvold, was promoted to CFO.
RATINGS SNAPSHOT
Overall rating: C
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 CELU | $1.68 | COMPARE |
 NUWE | $2.31 | COMPARE |
 HEPA | $0.07 | COMPARE |
 SYRA | $0.07 | COMPARE |
 XAGE | $0.48 | COMPARE |
 CCM | $4.00 | COMPARE |
 PTPI | $0.01 | COMPARE |